Similar articles

• Endocrine and clinical aspects of new compounds for treatment of hormone-related cancer in gynecology.

  von Matthiessen H, Distler W. von Matthiessen H, et al. Recent Results Cancer Res. 1990;118:190-5. doi: 10.1007/978-3-642-83816-3_19. Recent Results Cancer Res. 1990. PMID: 2146725 No abstract available.
• Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer.

  Anderson ED, Forrest AP, Levack PA, Chetty U, Hawkins RA. Anderson ED, et al. Br J Cancer. 1989 Aug;60(2):223-6. doi: 10.1038/bjc.1989.256. Br J Cancer. 1989. PMID: 2527549 Free PMC article.
• Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors.

  Bakker GH, Setyono-Han B, Portengen H, De Jong FH, Foekens JA, Klijn JG. Bakker GH, et al. Endocrinology. 1989 Sep;125(3):1593-8. doi: 10.1210/endo-125-3-1593. Endocrinology. 1989. PMID: 2527151
• [Long-term results of adjuvant endocrine therapy for hormone receptor-positive breast cancer].

  Semilgazov VF, Manikhas AG, Semiglazov VV, Bozhok AA, Dashian GA, Ivanov VG, Paltuev RM, Vasil'ev AG, Shchedrin DE, Ermachenkova AM, Nikitina IV, Pen'kov KD, Bessonov AA, Tabagua TT, Kolar'kova VV. Semilgazov VF, et al. Vopr Onkol. 2011;57(5):567-77. Vopr Onkol. 2011. PMID: 22238925 Review. Russian. No abstract available.
• [Estrogen and progesterone receptors in breast cancer].

  Sonoo H. Sonoo H. Nihon Rinsho. 2000 Apr;58 Suppl:146-53. Nihon Rinsho. 2000. PMID: 11025988 Review. Japanese. No abstract available.